6535 Share Price Performance
NT$128.50
-69.00 (-34.94%)
Price NT$128.50
Share PriceNT$128.50
6535 Community Narratives
There are no narratives available yet.
Recent 6535 News & Updates
No updates
Lumosa Therapeutics Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.45
- Gross Margin
- 49.38%
- Net Profit Margin
- -948.34%
- Debt/Equity Ratio
- 0%
Lumosa Therapeutics Co., Ltd. Competitors
About 6535
- Founded
- 2000
- Employees
- 43
- CEO
- WebsiteView website
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
Taiwanese Market Performance
- 7 Days: 2.0%
- 3 Months: 14.9%
- 1 Year: 14.0%
- Year to Date: 3.0%
Over the last 7 days, the market has risen 2.0%, driven by gains of 2.1% in the Financials sector. The market is up 14% over the last 12 months. Looking forward, earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading